NSCLC accounts for around 85% of all lung cancer cases, particularly in non-smoking patients
Category: astrazeneca
Up to 20% of prostate cancer cases are classified as castration-resistant
NSCLC accounts for around 85% of all lung cancer cases, particularly in non-smoking patients
Up to 20% of prostate cancer cases are classified as castration-resistant